Abstract

The present invention provides: a peptide set for quantifying and analyzing antigen proteins of individual subtypes from a specimen containing antigen proteins of a plurality of SARS-CoV-2 subtypes; and a method for simultaneously and quantitatively analyzing antigen proteins of SARS-CoV-2 subtypes according to types thereof, using same. The peptide set comprises one or more peptides specific to individual SARS-CoV-2 subtypes, selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 3, and a peptide common to SARS-CoV-2 subtypes, selected from SEQ ID NO: 4 or SEQ ID NO: 5.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/534 - Production of labelled immunochemicals with radioactive label
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Goods & Services

pre-filled syringes for medical purposes; pharmaceutical syringes prefilled with medical botulinum toxin as the main ingredient; filled syringes for medical purposes [containing pharmaceuticals]; injectable dermal fillers; skin hydrators being injectable dermal fillers. medical apparatus for injecting fillers; disposable hypodermic syringes for surgical use.

Abstract

The present invention relates to a vaccine composition for preventing SARS-CoV-2, comprising mRNA encoding an S mutant antigen of SARS-CoV-2 virus, wherein a vaccine for preventing SARS-CoV-2 according to the present invention exhibits excellent stability and high immunogenicity in vivo, and the vaccine is thus easy to store and use, and excellent preventive effect thereof against COVID-19 can be expected.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 37/04 - Immunostimulants

Abstract

The present disclosure relates to a mRNA delivery composition comprising cationic lipid-based liposome. The mRNA delivery composition according to the present disclosure is superb in terms of storage stability and exhibits high intracellular delivery and expression rates in vivo and thus, can enhance the stability and efficiency of mRNA vaccines for cancer therapy or mRNA vaccines for prevention of viral infections.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 8/14 - Liposomes
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

in vivoin vivo expression, and thus can improve the stability and efficiency of mRNA vaccines for treating cancer or mRNA vaccines for preventing viral infection, and other mRNA vaccines or treatments.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/12 - Antivirals
• A61P 31/04 - Antibacterial agents
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/14 - Liposomes

Abstract

in vivoin vivo and is thus easy to store and use, and is expected to have an excellent preventive effect against COVID-19.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A cationic liposome having the effect of inhibition of red blood cell hemolysis induced by saponin is disclosed. More particularly, a composition for inhibiting red blood cell hemolysis by saponin comprising a cationic liposome containing an unsaturated lipid, a composition for immunity enhancement and a composition for drug delivery comprising the composition for inhibiting red blood cell hemolysis by saponin, and a drug delivery carrier and a drug-carrier complex comprising a cationic liposome containing an unsaturated lipid are disclosed. A cationic liposome having the effect of inhibition of red blood cell hemolysis induced by saponin is disclosed. More particularly, a composition for inhibiting red blood cell hemolysis by saponin comprising a cationic liposome containing an unsaturated lipid, a composition for immunity enhancement and a composition for drug delivery comprising the composition for inhibiting red blood cell hemolysis by saponin, and a drug delivery carrier and a drug-carrier complex comprising a cationic liposome containing an unsaturated lipid are disclosed. Saponin exhibits a wide range of pharmacological and biological activities, such as anti-inflammatory activity, etc., including strong and effective immunological activity, and thus is effectively used medically and pharmaceutically, but has a disadvantage of causing hemolysis to red blood cells. Although saponin is generally used along with cholesterol, etc. to inhibit the hemolysis of saponin, it is confirmed herein that red blood cell hemolysis by saponin can be inhibited using a cationic liposome, which is more effective and economical in inhibiting the hemolysis of saponin. Therefore, saponin can be more usefully applied to the manufacture of immunity enhancers, drug delivery carriers, etc.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin

Abstract

in vivoin vivo, and the vaccine is thus easy to store and use, and excellent preventive effect thereof against COVID-19 can be expected.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/51 - Nanocapsules
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 31/14 - Antivirals for RNA viruses
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

in vivoin vivo and thus, can enhance the stability and efficiency of mRNA vaccines for cancer therapy or mRNA vaccines for prevention of viral infections.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 8/14 - Liposomes
• A61K 8/60 - SugarsDerivatives thereof
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to a cationic liposome having the effect of inhibiting saponin-induced hemolytic action on erythrocytes, and, more specifically, to: a composition for inhibiting saponin-induced erythrocyte hemolysis, containing a cationic liposome that contains an unsaturated lipid; an immune enhancement composition and a drug delivery composition which contain same; and a drug carrier and a drug-carrier complex which contain a cationic liposome that contain an unsaturated lipid. Saponin includes strong and effective immunological activity to exhibit broad pharmacological and biological activity such as anti-inflammatory activity, and thus can be medically and pharmaceutically effective, but has the disadvantage of causing erythrocyte hemolysis. Therefore, saponin is generally used together with cholesterol and the like so that the hemolytic action thereof is inhibited, but it has been identified in the present invention that saponin-induced erythrocyte hemolysis can be inhibited using a cationic liposome, which is more effective for inhibiting saponin-induced hemolysis on erythrocytes and is economical. Thus, according to the present invention, saponin can be more effectively used in preparing an immunostimulant, a drug delivery vehicle and the like.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention provides a kit and lens for prevention, alleviation, or promotive rehabilitation of corneal damage, which each have an excellent prophylactic or alleviative effect on corneal damage.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 27/02 - Ophthalmic agents
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• G02C 7/04 - Contact lenses for the eyes
• G02C 7/02 - LensesLens systems
• B29D 11/00 - Producing optical elements, e.g. lenses or prisms

Abstract

A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention provides a pharmaceutical composition having an excellent anti-inflammatory effect, thereby enabling effective prevention or treatment of inflammatory diseases such as reperfusion injury, periodontitis, arthritis, pressure sore inflammation, wound inflammation or dermatitis, and provides an anti-inflammatory cosmetic composition to be used as a raw material of cosmetic products that can be used for various inflammatory skin diseases.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/12 - Antivirals
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A61K 31/739 - Lipopolysaccharides
• A61K 39/002 - Protozoa antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens

Abstract

The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.

IPC Classes  ?

• A61K 31/739 - Lipopolysaccharides
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08L 5/00 - Compositions of polysaccharides or of their derivatives not provided for in group or
• A61K 39/25 - Varicella-zoster virus
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/002 - Protozoa antigens
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• A61K 39/12 - Viral antigens
• A61K 39/108 - EscherichiaKlebsiella

Abstract

The present invention relates to an immune response regulatory substance having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an immune response regulatory substance, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune response regulatory substance of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having lox toxicity. In addition, a vaccine containing the immune response regulatory substance of the present invention contains both an immune response regulatory substance and an alum, thereby improving immune enhancement effects compared with when using only the immune response regulatory substance.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/002 - Protozoa antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to an immunity enhancing composition including an immune response regulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an antigen, an immune response regulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response regulator is used alone.

IPC Classes  ?

• A61K 39/25 - Varicella-zoster virus
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 39/12 - Viral antigens
• A61K 39/002 - Protozoa antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a novel attenuated Pseudomonas aeruginosa improved in productivity and safety and a vaccine composition for prevention of Pseudomonas aeruginosa infection, comprising the same and, more particularly, to attenuated Pseudomonas aeruginosa of Deposit Accession number KCTC 12901BP, KCTC 12902BP, KCTC 12903BP, or KCTC 12904BP, and a vaccine composition for preventing Pseudomonas aeruginosa infection, comprising the same.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12N 1/36 - Adaptation or attenuation of cells
• A61K 39/104 - Pseudomonas
• C12R 1/38 - Pseudomonas

Abstract

The present invention provides a method for preparing L1 virus-like particles (VLP) of HPV. The method of the present invention first removes impurities through ammonium sulfate precipitation and then, secondly, removes impurities through dialysis in a solution containing 0.35-0.60 M of salts, thereby producing a high purity HPV L1 protein even though a chromatographic step is implemented one time.

IPC Classes  ?

• C07K 1/16 - ExtractionSeparationPurification by chromatography
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Abstract

The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present invention relates to: a pharmaceutical composition for reducing or inhibiting scar formation, including bone morphogenetic protein 7 (BMP-7) and a specific diluting agent; and a method for reducing or inhibiting scar formation by using the same. The composition of the present invention can be effectively used as an eye drop and the like for preventing scar formation which can be caused by plastic surgery, corneal laser surgery and the like.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 47/40 - CyclodextrinsDerivatives thereof

Abstract

The present invention relates to an adjuvant composition for an influenza vaccine and to a pharmaceutical composition of an influenza vaccine comprising same. The deacylated non-toxic LOS and Alum used together as an adjuvant may exhibit superior immunostimulation effects in an immune reaction to the influenza and have little toxicity, and therefore, have significantly excellent safety. Accordingly, the adjuvant composition and the pharmaceutical composition of the present invention can be valuably used as an influenza vaccine.

IPC Classes  ?

• A61K 39/108 - EscherichiaKlebsiella
• A61K 39/02 - Bacterial antigens
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/29 - Hepatitis virus
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 39/07 - Bacillus
• A61K 39/095 - Neisseria
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61K 39/25 - Varicella-zoster virus
• A61K 39/102 - PasteurellaHaemophilus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to an immune auxiliary composition, a vaccine composition and an anticancer drug composition comprising a non-toxic diacyl lipooligosaccharide having a stable structure and an oligodeoxynucleotide having an immunostimulatory action. The two different active ingredients comprised in the composition of the present invention give rise to a synergetic effect, and can be used as an anticancer drug of low toxicity and outstanding immunogenicity. Also, according to the present invention, it is possible to use a single microbial strain to straightforwardly produce a safe anticancer drug comprising a non-toxic macromolecular substance derived from bacterial LPS and purified DNA exhibiting an efficacy equivalent to or better than BCG at low cost.

IPC Classes  ?

• C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C12N 1/20 - BacteriaCulture media therefor
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/12 - Viral antigens
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to: (a) (i) a L1 virus-like particle (VLP) of human papilloma virus (HPV) type 16, L1 VLP of HPV type 18, or a combination thereof; (ii) deacylated non-toxic LOS (Lipooligosaccharide); (b) a pharmaceutical vaccine composition for human cervical cancer containing a pharmaceutically acceptable carrier; and a method for manufacturing human papilloma virus (HPV) L1 virus-like particles (VLP). The vaccine composition for human cervical cancer of the present invention has superior Th1 type immune response (cellular immunity) and Th2 type immune response (humoral immunity) than CervarixTM and GardasilTM in the immunity against HPV, and thus has high efficiency as a vaccine for cervical cancer.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.

IPC Classes  ?

• C07K 14/515 - Angiogenic factorAngiogenin
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Disclosed is a composition for treating retinopathy comprising thrombin derived peptide as an effective component.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

Disclosed is a composition for treating cancer including oligodeoxynucleotides and LPS-derived non-toxic lipopolysaccharides as effective components.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/739 - Lipopolysaccharides
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed is a composition for treating vascular diseases by acting on abnormal angiogenesis by means of secretion of angiopoietins.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans